Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Hims & Hers Health closed Wednesday at $29.54, up fractionally on the day but essentially flat on the week, with the short position continuing its slow retreat from August highs even as the structural bear thesis remains firmly in place.
Short covering has been steady, and the direction is unchanged from last week's note. Short interest now stands at 23.8% of the free float, down from around 24.2% a week ago and off roughly 10% over the past month. Peak short interest in mid-August sat closer to 25%, so around 6 million shares have been returned over that stretch. The pace remains unhurried. Cost to borrow has edged up slightly on the week to 0.53%, but is well below the 0.80% readings from six weeks ago, and that low borrowing cost for a stock this heavily shorted is the clearest sign there is no squeeze dynamic forcing short sellers to cover. Availability has loosened materially this week, climbing to 84% from around 58% at the end of September. That swing is worth noting: a month ago borrow availability was as tight as 50%, and the easing suggests lenders have been returning shares to the pool as shorts cover, making the path back in more accessible for anyone who wants to rebuild a position. The ORTEX short score of 71.0 has barely moved in a fortnight, consistent with a stock the model still characterises as carrying meaningful short-side conviction despite the gradual unwind. Options are not adding tension: the put/call ratio of 0.55 is exactly in line with its 20-day average, with a z-score near zero and a 52-week range that runs from 0.51 to 1.33. Options traders are neither hedging into November nor pricing in a squeeze.
The Street remains cautious but not outright negative. JP Morgan assumed coverage in September with a Neutral rating and a $32 target, a choice that sets the tone for a consensus sitting entirely in Hold territory across 11 analysts, with a mean target of $31.15 against a current price of $29.54. That implies modest upside, but nobody is stepping up to make a strong call. Barclays, the lone Overweight, trimmed its target to $35 from $39 in August. Most other desks raised targets modestly after Q2 results before settling into a wait-and-see posture. The bull case centres on a subscriber base of nearly 2.9 million, 38% revenue growth to $753 million in Q2, and a raised full-year revenue guide of $3.1 billion to $3.3 billion. The bear case is about the cost of that growth: gross margin fell to 63.8% from 69%, operating cash flow was negative $35.9 million, free cash flow negative $68.2 million, and the company carries $1.37 billion in debt against $841 million in cash. Factor scores lean toward the bears on quality and near-term earnings momentum, with EPS surprise ranking in the bottom 1st percentile and a short score rank in the 4th percentile. Forward earnings growth expectations remain elevated, the 12-month forward EPS year-on-year increase scores in the 60th percentile, but execution risk is clearly what the consensus is pricing.
One ownership dynamic is worth carrying forward. CEO Andrew Dudum holds a Schedule 13D filing on the register, making him a named activist-style holder by SEC classification. His last disclosed stake was 9.4% of the class, down from 10.3% on the prior filing. The reduction in stake is modest, and his institutional ownership data separately shows 16.6 million shares held as of late August. BlackRock is the largest institutional holder at 12.3% and added 2.4 million shares in the most recent reported quarter. State Street and JP Morgan Asset Management also added shares. On the insider trading side, every transaction in the past 90 days has been a sale, with the CFO, CLO and COO all selling under pre-arranged 10b5-1 plans. The net 90-day insider figure is a disposal of around 135,000 shares worth roughly $3.9 million. Plan sales are compensation mechanics rather than conviction signals, but the absence of any open-market buying at a price level management has repeatedly described as undervalued is a data point the bears will keep referencing.
The next earnings print is set for 2 November. After the most recent Q2 result in August, the stock fell 3.4% on the day and 9.4% over the following five trading sessions. The Q1 print, by contrast, produced a 15.8% single-day gain. The asymmetry in those two reactions captures the tension in the name precisely: a clean beat on margin as well as revenue can drive a sharp squeeze into a 24% short base, while a repeat of the Q2 margin miss risks accelerating the still-gradual covering into something more disorderly. With 25 days to the print, what to watch is whether the covering pace picks up as the date approaches, or whether cost to borrow and availability stay loose enough that shorts feel comfortable holding into the release.
See the live data behind this article on ORTEX.
Open HIMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
